CA3070848A1 - Biological binding molecules - Google Patents

Biological binding molecules Download PDF

Info

Publication number
CA3070848A1
CA3070848A1 CA3070848A CA3070848A CA3070848A1 CA 3070848 A1 CA3070848 A1 CA 3070848A1 CA 3070848 A CA3070848 A CA 3070848A CA 3070848 A CA3070848 A CA 3070848A CA 3070848 A1 CA3070848 A1 CA 3070848A1
Authority
CA
Canada
Prior art keywords
binding molecule
cell
subset
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070848A
Other languages
English (en)
French (fr)
Inventor
Ulrich Birsner
Hassan Jumaa
Holger Klapproth
Marc A. Kessemeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SINABIOSOLUTION GMBH
Original Assignee
AVA Lifescience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVA Lifescience GmbH filed Critical AVA Lifescience GmbH
Publication of CA3070848A1 publication Critical patent/CA3070848A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3070848A 2017-07-07 2018-07-05 Biological binding molecules Pending CA3070848A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17001166.2 2017-07-07
EP17001167 2017-07-07
EP17001167.0 2017-07-07
EP17001166 2017-07-07
EP18162672.2 2018-03-19
EP18162672.2A EP3424528A1 (de) 2017-07-07 2018-03-19 Biologische bindemoleküle
PCT/EP2018/068317 WO2019008129A1 (de) 2017-07-07 2018-07-05 Biologische bindemoleküle

Publications (1)

Publication Number Publication Date
CA3070848A1 true CA3070848A1 (en) 2019-01-10

Family

ID=64500047

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070848A Pending CA3070848A1 (en) 2017-07-07 2018-07-05 Biological binding molecules

Country Status (5)

Country Link
US (2) US11634487B2 (https=)
EP (4) EP3424527A1 (https=)
JP (2) JP7239575B2 (https=)
CA (1) CA3070848A1 (https=)
WO (2) WO2019008128A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424527A1 (de) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostisches verfahren
EP3733709A1 (de) * 2019-05-02 2020-11-04 AVA Lifescience Biologische bindemoleküle
CA3148214A1 (en) * 2019-05-02 2020-11-05 Ava Lifescience Gmbh Antigent binding domains and uses therefor
WO2020221463A1 (de) * 2019-05-02 2020-11-05 Ava Lifescience Gmbh Verfahren zur selektion biologischer bindemoleküle
IL310901A (en) * 2021-08-18 2024-04-01 Univ Pennsylvania Compositions and methods for chimeric antigen receptors specific to b cell receptors
EP4227321A1 (en) * 2022-02-10 2023-08-16 AVA Lifescience GmbH Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll
EP4476264A1 (en) 2022-02-10 2024-12-18 SinABioSolution GmbH Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
CA3262006A1 (en) * 2022-07-25 2024-02-01 Sinabiosolution Gmbh Humanized chimeric antigen receptors targeting the B-lymphocyte receptor in chronic lymphocytic leukemia and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP3539985A1 (en) * 2012-02-24 2019-09-18 AbbVie Stemcentrx LLC Anti sez6 antibodies and methods of use
US9770504B2 (en) * 2013-05-03 2017-09-26 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
SG11201601424PA (en) * 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
EP3424527A1 (de) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostisches verfahren

Also Published As

Publication number Publication date
US20200199225A1 (en) 2020-06-25
US11634487B2 (en) 2023-04-25
EP3424527A1 (de) 2019-01-09
JP2020526590A (ja) 2020-08-31
EP3424528A1 (de) 2019-01-09
WO2019008128A1 (de) 2019-01-10
JP2020527727A (ja) 2020-09-10
EP3615072A1 (de) 2020-03-04
US20200209246A1 (en) 2020-07-02
JP7239575B2 (ja) 2023-03-14
JP7271532B2 (ja) 2023-05-11
WO2019008129A1 (de) 2019-01-10
US11591391B2 (en) 2023-02-28
CA3070847A1 (en) 2019-01-10
EP3615073A1 (de) 2020-03-04

Similar Documents

Publication Publication Date Title
US11591391B2 (en) Biological binding molecule
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP7070932B2 (ja) Ｂａｆｆ－ｒ標的化キメラ抗原受容体修飾ｔ細胞及びその使用
JP2022515318A (ja) 抗体及びその用途
CN108138172B (zh) 抗体
CN114685655B (zh) Pd-1结合分子及其应用
JP7796160B2 (ja) 生物学的結合分子
CN114981301B (zh) Pd1和vegfr2双结合剂
KR20240004860A (ko) 디엘엘3에 대한 결합 분자 및 이의 용도
KR20230007299A (ko) Gpc3에 특이적인 항체 및 이의 용도
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
KR102800024B1 (ko) 항-ｍｙｌ9 항체
US20240287177A1 (en) Vhh-based nkp30 binders
CA3070847C (en) Diagnostic method
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
WO2024199454A1 (en) Antibodies and variants thereof against human cluster of differentiation 3 protein
AU2024218952A1 (en) Vhh-based nkp46 binders
CN121627890A (zh) 包含nk细胞的药物组合物及其抑制癌细胞的用途
AU2024296429A1 (en) Binding constructs
HK40105152A (zh) 对muc18特异性的抗体
CN121914273A (zh) 包含nk细胞的药物组合物及其制备方法以及用于抗癌的用途
CN113368232A (zh) 多特异性抗原结合蛋白及其应用
HK40089099A (en) Anti-tigit antibody and double antibody and their application

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220621

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240822

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520